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Developing myocardial cells respond to signals from
the endocardial layer to form a network of trabeculae
that characterize the ventricles of the vertebrate
heart. Abnormal myocardial trabeculation results in
specific cardiomyopathies in humans and yet trabec-
ular development is poorly understood. We show
that trabeculation requires Brg1, a chromatin remod-
eling protein, to repress ADAMTS1 expression in the
endocardium that overlies the developing trabecu-
lae. Repression of ADAMTS1, a secreted matrix met-
alloproteinase, allows the establishment of an extra-
cellular environment in the cardiac jelly that supports
trabecular growth. Later during embryogenesis,
ADAMTS1 expression initiates in the endocardium
to degrade the cardiac jelly and prevent excessive
trabeculation. Thus, the composition of cardiac jelly
essential for myocardial morphogenesis is dynami-
cally controlled by ADAMTS1 and its chromatin-
based transcriptional regulation. Modification of the
interveningmicroenvironmentprovides amechanism
by which chromatin regulation within one tissue layer
coordinates the morphogenesis of an adjacent layer.
INTRODUCTION
Cardiac progenitor cells of mesoderm origin differentiate into
both the myocardium and the endocardium that form the basic
layers of the heart, respectively. As development proceeds,
these two cell layers interact with each other to form specialized
structures of the heart such as heart valves and myocardial tra-
beculae (reviewed in Harvey, 2002). Myocardial trabeculation is
a key morphogenetic event in heart development that begins
at embryonic day E9.0 in mice, when clusters of myocardial cells
in the ventricles protrude into the extracellular matrix (cardiac
jelly) separating the myocardium from the endocardium. These
nascent trabeculae continue to expand, forming long, thin pro-
jections. Contiguous with this expansion, ventricular endocardial298 Developmental Cell 14, 298–311, February 2008 ª2008 Elseviercells invaginate between the myocardial projections. By E14.5,
the ventricular endocardium becomes tightly associated with the
myocardial cells as the cardiac jelly dissipates. Finally, the tra-
beculae largely collapse to thicken the compact layer of myocar-
dium (compaction of myocardium). Excessive trabeculation or
a failure of the trabeculae to undergo compaction causes cardio-
myopathy and heart failure in humans (Jenni et al., 1999). Despite
its importance, very little is known about the genetic and molec-
ular programs that initiate and terminate trabeculation.
Several studies implicate the importance of the exchange of
intercellular signals between the endo- and myocardium during
trabeculation. Neuregulin is produced by endocardial cells and
acts through the myocardial receptors ErbB2 and ErbB4 to drive
myocardial trabeculation (Gassmann et al., 1995; Kramer et al.,
1996; Lee et al., 1995). Conversely, vascular endothelial growth
factor (VEGF) and angiopoietin signal from the myocardium to
the endocardium to regulate trabeculation (Ferrara et al., 1996;
Sato et al., 1995; Suri et al., 1996). For these signals to be trans-
mitted appropriately, they must traverse the cardiac jelly lying
between the endo- and myocardium. Interestingly, both neure-
gulin and VEGF signaling are modified by extracellular matrix
components, suggesting that the establishment of the correct
cardiac jelly complement is critical for appropriate receipt of
signals between ventricular endo- and myocardium. Consistent
with this idea, mice lacking either hyaluronan synthase-2 (Has-
2), an enzyme required for production of the mucopolysaccha-
ride hyaluronan, or versican, a chondroitin sulfate proteoglycan,
do not develop trabeculae (Camenisch et al., 2000; Mjaatvedt
et al., 1998; Yamamura et al., 1997). The decrease in ventricular
cardiac jelly that is observed concomitant with the termination of
trabeculation further raises the possibility that active degrada-
tion of the cardiac jelly participates in this process. This could
be accomplished by a decrease in expression of cardiac jelly
components or a change in expression or activity of extracellular
matrix regulators. Included in the latter class are the hyaluroni-
dases and members of the matrix metalloproteinase family, no-
tably the ADAMTS (a disintegrin and metalloproteinase with
thrombospondin motif) family, whose substrates include Versi-
can (reviewed in Porter et al., 2005). While both Has-2 and Ver-
sican, among other ECM components, and ADAMTS family
members exhibit dynamic expression patterns during cardiacInc.
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1998; Klewer et al., 2006; Thai and Iruela-Arispe, 2002), the
mechanisms of their transcriptional regulation are unknown.
Alteration of chromatin structure provides an important source
of gene regulation by determining the accessibility of DNA regu-
latory elements to transcription factors. Chromatin can be mod-
ified noncovalently by the rearrangement of nucleosomes cata-
lyzed by ATP-dependent chromatin remodeling complexes to
facilitate both transcriptional activation and repression (Dunaief
et al., 1994). The Brg1-associated-factor (BAF) complex is
a ten subunit complex in which the ATPase component is en-
coded by one of two genes, Brg1 or Brm. Although both genes
are broadly expressed, Brg1 null mice show peri-implantation
lethality (Bultman et al., 2000), while Brm null mice are viable
(Reyes et al., 1998). Recent reports suggest that BAF subunits
are required for cardiac development. BAF180, a specific sub-
unit of the PBAF form of the BAF complex, regulates cardiac
chamber maturation and is required for survival past mid-em-
bryogenesis (Wang et al., 2004). RNA interference of BAF60c,
which is expressed throughout the developing heart, results in
severe heart defects including a single ventricle, a poorly devel-
oped outflow tract, and no trabeculation (Lickert et al., 2004).
While expression of several myocardial transcripts is reduced
in BAF60c knockdown embryos, the molecular basis of these
phenotypes is unclear. It is also unknown whether the BAF com-
plex is required in the endocardium, myocardium, or both for
cardiac morphogenesis.
We use tissue-specific deletion of Brg1 in both the endocar-
dium and myocardium to study the roles of the BAF complex
in each tissue during cardiogenesis. The absence of Brg1 by
embryonic day E9.5 produces trabeculation defects when it is
deleted from the endocardium but not the myocardium. Neither
deletion causes widespread changes in transcription of several
key regulators of cardiac development. Instead, the trabeculation
defects in the absence of endocardial Brg1 result from derepres-
sion of a secreted matrix metalloproteinase, ADAMTS1, which
normally only increases in expression later in development to
prevent excessive trabeculation. The increase in ADAMTS1
causes premature breakdown of the cardiac jelly and termination
of trabeculation, demonstrating that cardiac jelly regulation by
endocardial cells coordinates maturation of ventricular myocar-
dium. Further, our data indicate that the BAF complex has a sur-
prisingly specific role in the developing heart after the basic
tissue layers are formed. More broadly, we demonstrate that
chromatin remodeling can influence tissue morphogenesis
through regulation of the microenvironment.
RESULTS
Endothelial Brg1 Is Required for Yolk Sac
Vasculogenesis and Primitive Erythropoiesis
To study the function of the BAF complex in endocardial cells, we
specifically deleted the core Brg1 subunit throughout the endo-
thelium by crossing mice carrying a loxP-flanked allele of Brg1
(Sumi-Ichinose et al., 1997) with Tie2Cre transgenic mice (Kisa-
nuki et al., 2001). Brg1 was normally expressed in the nuclei of
both myocardial and endocardial cells, as well as all surrounding
tissues (Figure 1A). In contrast, Brg1 was undetectable in the
endocardial cells of Tie2Cre;Brg1F/F embryos, as marked by ex-Devepression of the transcription factor NFATc1 (de la Pompa et al.,
1998; Ranger et al., 1998), but remained expressed in all other
nonendothelial tissues (Figure 1B, Figure S2, see the Supple-
mental Data available with this article online). This deletion was
first evident at E9.0 (data not shown). At E9.5, Tie2Cre;Brg1F/F
embryos were of comparable size to littermate controls
(Figure 1C). However, they appeared pale due to a decrease in
circulating red blood cells caused by defects in yolk sac vasculo-
genesis and primitive hematopoiesis (Supplemental Data and
Figure S1). In contrast, the basic pattern of the embryonic vascu-
lature was intact in E9.5 Tie2Cre;Brg1F/F embryos. By E10.5,
Tie2Cre;Brg1F/F embryos were considerably smaller than their
littermates (Figure 1D) and none survived to E11.5.
Brg1 Is Required in the Endocardium for Trabeculation
We examined hematoxylin and eosin stained (H&E) sections of
Tie2Cre;Brg1F/F embryos between E9.5 and E10.5 and found de-
fects in trabeculation of the heart ventricles. Normally, nascent
myocardial trabeculae are present by E9.5, forming discrete out-
growths of myocardial cells migrating into the cardiac jelly. In
Tie2Cre;Brg1F/F embryos, therewas only limited formation of tra-
beculae at E9.5 (Figures 1E and 1F). By E10.5, when trabeculae
were normally extensive, Tie2Cre;Brg1F/F embryos had very
sparse trabeculation (Figure S2). We double stained E10.5
embryos for MF20, a myocardial marker, and PECAM, an endo-
cardial marker, to assess the organization of the two cell layers
(Figures 1G and 1H). Although both cell types were present in
Tie2Cre;Brg1F/F embryos, PECAM-positive endocardial cells
did not invaginate around MF20 positive cardiomyocytes
outgrowing from the compact layer, consistent with histological
observations.
We quantified the extent of the trabeculation defect by mor-
phometric measurements of the thickness of individual trabecu-
lae, the total area of trabecular myocardium, and the length of the
compact wall in anti-PECAM and anti-MF20 double stained
sections. The trabecular thickness was significantly reduced at
both E9.75 and E10.5 in Tie2Cre;Brg1F/F embryos (Figure 1I,
Figure S2). At E10.5, the compact layer was also significantly
thinner than control embryos (Figure S2). We measured the total
degree of trabecular atrophy by normalizing trabecular area to
compact wall length. This analysis showed a significant de-
crease in the extent of trabeculation as well as the size of each
trabecular sheet at E9.75 and E10.5 in Tie2Cre;Brg1F/F embryos
(Figure 1J). These results demonstrate that Brg1 has critical roles
in the endocardium to regulate trabecular development.
Myocardial Brg1 Is Not Required for Trabeculation
between E9.5 and E10.5
To investigate the possibility that Brg1 is also required in ventric-
ular myocardium for trabeculation, we deleted Brg1 using the
myocardial-expressed SM22aCre transgene (Holtwick et al.,
2002; Umans et al., 2007; Figure S3). Less than 5% of ventricular
myocardial cells in E9.5 SM22aCre;Brg1F/F embryos expressed
detectable levels of Brg1, with no evidence of deletion in endo-
cardial cells (Figures 2A and 2B, Figure S3). In contrast to Tie2-
Cre;Brg1F/F embryos, SM22aCre;Brg1F/F embryos had no gross
defects in embryonic development up to E10.5 (Figures 2C and
2D). H&E staining of sections through the hearts of these em-
bryos demonstrated that trabeculation was normal (Figures 2Elopmental Cell 14, 298–311, February 2008 ª2008 Elsevier Inc. 299
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(A and B) Paraffin sections from wild-type (A) and Tie2Cre;Brg1F/F (B) E9.5 embryos were double stained with an anti-Brg1 antibody (green) and an anti-NFATc1
antibody (cyan) to mark endocardial cells. The arrows point to endocardial cells.
(C and D) Images of E9.5 and E10.5 wild-type and Tie2Cre;Brg1F/F embryos. A, atrium; V, ventricle.
(E and F) Hematoxylin and eosin (H&E) stained paraffin sections showing E9.5 wild-type and Tie2Cre;Brg1F/F heart ventricles. Arrows denote ventricular endo-
cardial cells.
(G and H) E10.5 wild-type and Tie2Cre;Brg1F/F frozen heart sections stained with antibodies against PECAM (green) and MF20 (cyan) to mark the endocardium
and myocardium, respectively.
(I and J) Morphometric analysis of trabecular thickness (I) and the ratio of trabecular area to compact wall length (J) by measurement of sections stained as in (G)
and (H) from E9.25, E9.75, and E10.5 wild-type and Tie2Cre;Brg1F/F embryos. Error bars represent one standard deviation. Three hearts were measured for each
group and p values were calculated using two-tailed Student’s t tests.and 2F). Therefore, myocardial BAF complexes do not regulate
trabeculation between the time Brg1 was deleted in these mice
(between E8.5 and E9.5) and E10.5.
Deletion of Brg1 after E9.0 Does Not Have Widespread
Effects on Cardiac Gene Expression
Tounderstandthemolecularbasis for themyocardial trabeculation
defects in Tie2Cre;Brg1F/F embryos, we examined the expression
of myocardial genes important for this process. The expression of
Nkx2.5, which is required for trabeculation (Lyons et al., 1995), and
NPPA was decreased in BAF60c RNAi embryos (Lickert et al.,
2004). However, bothNkx2.5 andNPPAwere expressed normally
in the myocardium of both Tie2Cre;Brg1F/F (Figures 3A–3D) and
SM22aCre;Brg1F/F embryos (Figure S3). The defects in Nkx2.5
and NPPA expression seen in the BAF60c RNAi mice may there-
fore reflect a requirement for the BAF complex prior to the onset
of Brg1 deletion using Tie2Cre or SM22aCre. BMP10, which is
also required for trabeculation (Chen et al., 2004) and whose ex-
pression is regulatedbyendocardial signals (H.C.andW.S.unpub-300 Developmental Cell 14, 298–311, February 2008 ª2008 Elsevierlished data), was also expressed normally in Tie2Cre;Brg1F/F em-
bryos (Figures 3E and 3F). Additional myocardial proteins, such
asMF-20andActinin (Figures1Gand1H,FigureS4) or transcripts,
including GATA4, ErbB2, Hey1, MEF2C, VEGF, MEST, and Irx4,
werealsoexpressednormally inTie2Cre;Brg1F/Fembryos (Figures
S5 and S6). Therefore, signals originating from the endocardium
required for maturation of ventricular myocardium are unaffected
by the absence of endocardial Brg1.
Next, we used RNA in situ hybridization to survey the expres-
sion of endocardial transcripts in Tie2Cre;Brg1F/F embryos to de-
termine if Brg1 was required for their transcription. We examined
neuregulin, Tie1, Tie2, and VEGFR2 because each of these sig-
nalingmolecules and/or their receptor/ligand partners have been
shown to be required for trabeculation (Ferrara et al., 1996;
Meyer and Birchmeier, 1995; Meyer et al., 1997; Sato et al.,
1993, 1995; Suri et al., 1996). However, they were all expressed
normally in E9.5 Tie2Cre;Brg1F/F embryos (Figures 3G–3L,
Figure S5). Recently, the Notch pathway has been shown to be
required for trabeculation by regulating expression of neuregulinInc.
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Normal expression of these transcripts and the Notch target
Hey1 in Tie2Cre;Brg1F/F embryos (Figure S5) suggests the Notch
pathway is not perturbed by the absence of endocardial Brg1.
These results indicate that endocardial cells maintained their
differentiated state and did not have widespread changes in
transcription in the absence of Brg1. Rates of apoptosis and
cellular proliferation were also not significantly changed in E9.5
Tie2Cre;Brg1F/F embryos (Figure S4). Together, these results
suggest that the BAF complex has a restricted role in regulating
the function rather than differentiation of endocardial cells to
control trabecular morphogenesis.
Endocardial Brg1 Is Required for Establishment
of Ventricular Cardiac Jelly
Several extracellular matrix (ECM) components, notably hyalur-
onan and Versican, are required for trabeculation (Camenisch
et al., 2000; Yamamura et al., 1997). Interestingly, histological
analysis of Tie2Cre;Brg1F/F embryos showed an apparent de-
crease in the amount of ECM, termed the cardiac jelly, separat-
Figure 2. Loss of Myocardial Brg1 Does Not
Have Major Effects on Cardiac Morphogen-
esis between E9.0 and E10.5
(A and B) E9.5 wild-type and SM22aCre;Brg1F/F
heart sections are double immunostained for
Brg1 (green) and smooth muscle actin (SMactin)
to mark the myocardium (red). Nuclei (blue) are
stained using Hoechst. Arrows indicate ventricular
endocardial cells.
(C and D) Gross images of E10.5 wild-type and
SM22aCre;Brg1F/F embryos.
(E and F) H&E stained heart sections of E9.5 wild-
type and SM22aCre;Brg1F/F embryos. A, atrium;
V, ventricle.
ing the ventricular endocardium from the
myocardium (Figures 1E and 1F). We
stained E9.5 heart sections with Alcian
blue (pH 2.5) to detect the presence of
acidic mucopolysaccharides, including
hyaluronan, and sulfated and carboxyl-
ated proteoglycans, such as Versican. In
Tie2Cre;Brg1F/F embryos, there was
a clear decrease in the amount of Al-
cian-blue-positive material in the ventric-
ular cardiac jelly (Figures 4A and 4B). We
examined Tie2Cre;Brg1F/F embryos for
the presence of hyaluronan by staining
sections with biotinylated hyaluronan
binding protein. Hyaluronan was found
throughout the cardiac jelly, but was
nearly absent in the ventricular cardiac
jelly of Tie2Cre;Brg1F/F embryos (Figures
4C and 4D). Similarly, Versican protein
levels were reduced in the ECM of the
ventricles (Figures 4E and 4F). Neverthe-
less, transcription of Has-2 and UDP-
glucose-dehydrogenase (UGDH), two en-
zymes required for hyaluronanproduction,
and versican persisted in the ventricles of Tie2Cre;Brg1F/F em-
bryos (Figures 4I–4L, Figure S5). Perlecan, a heparan sulfate pro-
teoglycan required for heart development (Costell et al., 2002),
was also transcribed normally (Figure S5), although Perlecan pro-
tein levelswere alsodiminished in ventricular cardiac jelly byE9.75
(Figure 4G and 4H). Interestingly and as previously reported (Hen-
derson and Copp, 1998), versicanwas expressed in myocardium
while Has-2 transcripts were found at higher levels in ventricular
myocardium compared to the neighboring endocardium. These
results are consistent with the observation that the myocardium
is the primary source of cardiac jelly components (Manasek et al.,
1973). The normal transcription of Has-2, UGDH, versican, and
perlecan suggest that a change in expression of a modulator of
ECM, rather than the components themselves, accounts for the
ECM deficiency in Tie2Cre;Brg1F/F embryos.
ADAMTS1 Is Derepressed in the Absence
of Endocardial Brg1
We employed a candidate gene approach to identify transcripts
whose misregulation in Tie2Cre;Brg1F/F embryos could causeDevelopmental Cell 14, 298–311, February 2008 ª2008 Elsevier Inc. 301
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Trabeculation Are Expressed Normally in Tie2Cre;Brg1F/F Embryos
(A–D, G–L) In situ hybridizations on paraffin sections of E9.5 wild-type and
Tie2Cre;Brg1F/F embryonic hearts for the indicated transcripts (stained brown
with DAB). The blue counter stain is hematoxylin.
(E and F) E9.5 wild-type and Tie2Cre;Brg1F/F embryos are whole-mount
stained for BMP10 transcripts (blue). Arrows indicate ventricular endocardial
cells. A, atrium; V, ventricle.302 Developmental Cell 14, 298–311, February 2008 ª2008 Elsevierthe observed ECMdefects (Figures S5 and S6). In our screen, we
included Hyal1, Hyal2, and Hyal3, the three hyaluronidases
whose potential upregulation could account for a decrease in
hyaluronan content. We also examined members of the matrix
metalloproteinase family, MMP1, MMP2, MMP3, MMP9, and
MMP13, each of which has been shown to degrade Versican
or related proteoglycans (reviewed in Flannery, 2006). Finally,
we checked expression of ADAMTS1, ADAMTS4, ADAMTS5,
ADAMTS8, ADAMTS9, and ADAMTS18, their proposed cofac-
tor, fibulin-1 (Lee et al., 2005), and their inhibitor TIMP3 (Kashi-
wagi et al., 2001). TheADAMTS family consists of 19 genes of the
metalloproteinase superfamily (reviewed in Porter et al., 2005),
which have been implicated in cardiac development (reviewed
in Manso et al., 2006). ADAMTS1, 4, 5, 8, 9, and 18 were chosen
for analysis because they have been described as Versicanases
and/or have been shown to express in endothelial cells (A.J.
Connolly, personal communication). In addition, ADAMTS1,
ADAMTS9, and Fibulin-1 have been reported to regulate endo-
cardial cushion development (Kern et al., 2006). Because TIMP3
is expressed in the developing endocardium (Brauer and Cai,
2002), we also examined whether its expression was decreased
in Tie2Cre;Brg1F/F embryos.
Among the 19 screened ECM-related transcripts, only
ADAMTS1 exhibited a clear change in expression in Tie2Cre;
Brg1F/F embryos (Figures S5 and S6). In these embryos,
ADAMTS1 was expressed at high levels in ventricular endocar-
dial cells relative to littermate controls while maintaining a low
level of expression in the myocardium (Figures 5A and 5B). To
confirm the observed increase in ADAMTS1 seen by in situ hy-
bridization, we performed RT-PCR analyses on mRNA from the
hearts of E9.5 embryos. Using quantitative RT-PCR and normal-
ization to HPRT, a ubiquitously expressed transcript, we found
that ADAMTS1 transcripts were present at 2.83 higher levels
in the Tie2Cre;Brg1F/F embryos (Figure 5C). A collection of other
myocardial and endocardial transcripts were not significantly
changed in expression, consistent with our in situ hybridization
experiments. An increase in ADAMTS1 expression could ac-
count for the subsequent decrease in Versican levels and, indi-
rectly, in the hyaluronan content of the ventricular cardiac jelly
as Versican contains hyaluronan-binding domains that may sta-
bilize hyaluronan levels (LeBaron et al., 1992). Consistent with
augmented ADAMTS1 activity, increased staining using an anti-
body that recognizes a specific cleavage product of Versican
(Neo-Versican) arising from ADAMTS activity was observed in
E9.25 Tie2Cre;Brg1F/F embryos prior to further dissipation of
Versican levels by E9.5 (Figures 5D and 5E).
We examined whether repression of ADAMTS1 by Brg1 was
a primary effect of Brg1 in endocardial cells using loss-of-func-
tion studies of Brg1 in cultured cells. We used human umbilical
vein endothelial cells (HUVECs), which express ADAMTS1 (Nor-
ata et al., 2004), as a heterologous source of primary cells. We
reduced expression ofBrg1 using RNA interference and assayed
changes in ADAMTS1 transcript levels. Lentiviral mediated ex-
pression of two separate small hairpin RNAs targeting Brg1 pro-
duced an increase in ADAMTS1 expression proportionate to the
degree of Brg1 transcript knockdown (Figure 5F). The most
robust knockdown, to 21% of normal Brg1 levels, resulted in
a 3-fold increase in endogenous ADAMTS1 transcripts. This re-
sult supports our in vivo observations that loss of endocardialInc.
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in Ventricular Cardiac Jelly
(A and B) Alcian blue staining of paraffin sections through ventricles of E9.5
wild-type and Tie2Cre;Brg1F/F embryos. The sections are counterstained
with nuclear fast red.
(C and D) Hyaluronan (HA) staining using biotinylated-HABP of wild-type and
Tie2Cre;Brg1F/F ventricle sections.
(E and F) Anti-Versican antibody staining of ventricle-containing sections of
wild-type and Tie2Cre;Brg1F/F hearts.
(G and H) Antibody staining of Perlecan in left ventricle sections of E9.75 wild-
type and Tie2Cre;Brg1F/F embryos.DeveBrg1 is the primary cause of the increase in endocardial
ADAMTS1 expression and demonstrates that similar repression
of ADAMTS1 by Brg1 occurs in additional endothelial cell
types.
Brg1 Directly Associates with the ADAMTS1 Locus
in Endothelial Cells
The upregulation of ADAMTS1 in HUVECs and endocardial cells
in the absence of Brg1 could represent a secondary effect of
misexpression of ADAMTS1 transcriptional regulators or could
be accounted for by a direct requirement for the BAF complex
in ADAMTS1 repression. To determine whether endogenous
Brg1 directly binds the ADAMTS1 locus, we performed chroma-
tin immunoprecipitation assays and quantitative PCR using
HUVECs as a source of material. We aligned the mouse, dog,
rat, and human genomes to identify conserved regions in the
ADAMTS1 locus that may act as sites for Brg1 association
(Figure 6A). Primer pairs within each of these regions were
designed for amplification of DNA from immunoprecipitated
chromatin. Antibodies directed against Brg1 precipitated more
chromatin fragments from the immediate promoter area (3.73,
p < 0.002) and a conserved stretch in the first intron (4.63,
p < 0.03) relative to a control anti-GFP antibody (Figure 6B).
Limited or no enrichment was found for an upstream candidate
regulatory site (1.43, p < 0.13) or an unconserved region approx-
imately 30 kb upstream from the promoter (Figure 6B, data not
shown). These results support a model in which the BAF com-
plex directly binds the ADAMTS1 locus near the immediate pro-
moter region to maintain its repression in developing ventricular
endocardial cells.
We further tested this concept using luciferase reporter assays
with regions from the ADAMTS1 locus. We prepared four differ-
ent constructs that contained either a 2.0 kb immediate promoter
fragment or a longer 3.2 kb region that included the second con-
served region not bound by Brg1 each with or without the con-
served intron region cloned downstream of luciferase. Impor-
tantly, the reporter constructs were cloned into Epstein-Barr
Virus-derived pREP4 episomal vectors that contain the virus rep-
lication origin and express nuclear antigen EBNA-1. These vec-
tors become chromatinized when transfected into mammalian
cells and therefore are informative when studying the effects of
chromatin remodeling complexes (Liu et al., 2001). We trans-
fected each of the four reporter plasmids into SW13 adenocarci-
noma cells, which lack both Brg1 and its homolog Brm (Mu-
chardt and Yaniv, 1993) and therefore lack functional BAF
complexes, in the presence or absence of a cotransfected
Brg1-expressing plasmid. Expressing Brg1 in SW13 cells re-
stores BAF complex function. Lysates from each of the transfec-
tion experiments contained between 2.8- and 4.5-fold lower lu-
ciferase levels when Brg1 was restored to the cells (Figure 6C).
These results further support a model of direct repression of
ADAMTS1 by Brg1. The site of action is likely through the imme-
diate promoter region (Region 2) of the ADAMTS1 locus, as each
(I–L) In situ hybridizations for Has-2 (I) and (J) and versican (K) and (L) tran-
scripts on E9.5 wild-type and Tie2Cre;Brg1F/F heart sections. The staining in
(C–L) was developed with DAB (brown) and counterstained with hematoxylin.
Arrows indicate ventricular endocardial cells. V, ventricle; AVC, atrioventricular
canal.lopmental Cell 14, 298–311, February 2008 ª2008 Elsevier Inc. 303
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in common. The results also demonstrate that Brg1 activity, sep-
arate from Brm, is necessary and sufficient for repression of
ADAMTS1.
ADAMTS1 Derepression Terminates Trabeculation
To investigate whether the increase in ADAMTS1 expression un-
derlies the ECM defects in Tie2Cre;Brg1F/F embryos, we treated
cultured embryos (Chang et al., 2004) with GM6001, a broad
spectrum inhibitor of matrix metalloproteinases including
ADAMTS1 (Shimada et al., 2004). Wild-type embryos harvested
at E9.0 and treated with GM6001 for 36 hr developed relatively
Figure 5. ADAMTS1 Is Derepressed in the
Absence of Endocardial Brg1
(A and B) RNA in situ hybridization for ADAMTS1
transcripts (brown) on E9.5 wild-type and Tie2-
Cre;Brg1F/F ventricle sections.
(C) Quantitative RT-PCR (qRT-PCR) for ADAMTS1
and endocardial transcripts (Tie2, VEGFR2,
NFATc1), myocardial transcripts (Nkx2.5,
MEF2C, GATA4, Tbx5), or ECM-related tran-
scripts (versican, Has-2, UGDH) normalized to
HPRT expression using RNA from dissected
hearts of E9.5 wild-type and Tie2Cre;Brg1F/F em-
bryos. Error bars represent one standard devia-
tion. p < 0.002 (n = 3 wild-type and mutant) of
a nonsignificant change in ADAMTS1 in Tie2-
Cre;Brg1F/F hearts by a two-tailed Student’s t test.
(D and E) Antibody staining for a Versican cleavage
product (Neo-Versican) produced in ventricle
sections of E9.25 wild-type and Tie2Cre;Brg1F/F
embryos. Arrows denote subendocardial cardiac
jelly.
(F) qRT-PCR for ADAMTS1 and Brg1 transcripts
normalized toHPRT on RNA from cultured primary
human umbilical vein endothelial cells transduced
with a control lentivirus or one expressing small
hairpin RNA (shRNA) directed against Brg1 tran-
scripts. Experiment #1 used a different shRNA se-
quence from Experiments #2 and #3. Each exper-
imental set represents independent experiments
that varied in their extent of RNA interference of
Brg1.
normally (Figures 7A, 7B, 7E, and 7F).
Mock-treated Tie2Cre;Brg1F/F embryos
had severe defects in ventricle develop-
ment, even more so than seen in utero
at E10.5. They had an increase in com-
pact layer thickness, no trabeculation,
and a near complete absence of Alcian
blue staining in the subendocardial space
(Figure 7G). Tie2Cre;Brg1F/F embryos
treated with GM6001 remained growth-
retarded and pale, being unchanged in
gross appearance (Figure 7D). However,
they contained Alcian blue-positive
material in ventricular cardiac jelly and
exhibited a significant recovery of tra-
beculation (Figure 7H and 7M). GM6001-
treated Tie2Cre;Brg1F/F embryos also re-
covered expression of Versican and hyaluronan in the ventricular
cardiac jelly to levels seen in wild-type embryos (Figures 7I–7L,
7N, and 7O). These results indicate that the increase in
ADAMTS1 in Tie2Cre;Brg1F/F embryos is responsible for the col-
lapse of the ECM through proteolysis of Versican and the subse-
quent failure of trabeculation. A separate broad-spectrum MMP
inhibitor, minocycline (Paemen et al., 1996), which does not in-
hibit ADAMTS1 (Rodriguez-Manzaneque et al., 2002), did not
rescue trabeculation or cardiac jelly in cultured Tie2Cre;Brg1F/F
embryos (Figure S7). Together with the absence of changes in
expression of other matrix proteinases (Figures S5 and S6),
this finding indicates that an increase in ADAMTS1 alone largely304 Developmental Cell 14, 298–311, February 2008 ª2008 Elsevier Inc.
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(A) An alignment of theADAMTS1 locus between themouse and dog, human, and rat genomes, respectively. Increased conservation is shown by the height of the
colored curves. Blue regions are translated portions of exons, yellow is 50 untranslated region, and red indicates candidate regulatory regions. Three conserved
regions, labeled 1, 2, and 3, were selected for further analysis.
(B) Quantitative PCR analysis of anti-Brg1 immunoprecipitated chromatin from regions 1, 2, and 3 in human umbilical vein endothelial cells normalized to an
anti-GFP control antibody. Error bars represent one standard deviation and p values were determined by two-tailed Student’s t tests.
(C) Episome-based reporter assays using the indicated ADAMTS1 candidate regulatory regions cloned in luciferase expression plasmids cotransfected in SW13
cells with either a control or Brg1-expressing plasmid to restore BAF complexes to the cells. The luciferase activity is graphed relative to a cotransfected con-
stitutive Renilla luciferase control and error bars represent one standard deviation between 3 independent transfections. P values were calculated using unpaired
two-tailed Student’s t tests.accounts for the defective trabeculation in Tie2Cre;Brg1F/F
embryos.
Since GM6001 treatment did not rescue the hematopoietic
defects in Tie2Cre;Brg1F/F embryos, as shown by the absence
of red blood cells in sections of the cultured embryos
(Figure 7L), ADAMTS1 derepression does not cause all the phe-
notypes of Tie2Cre;Brg1F/F embryos. Consistent with this obser-
vation, ADAMTS1was not derepressed in other endothelial cells
in Tie2Cre;Brg1F/F embryos (Figure S8). This result indicates that
Brg1 may have an active and specific role in maintaining
ADAMTS1 repression in specific types of endothelial cells, in-
cluding endocardial cells, rather than a general requirement for
establishing the ADAMTS1 transcriptional ground state. This ob-
servation raises the question, why does ADAMTS1 need to be
repressed in developing ventricular endocardial cells? Interest-
ingly, cardiac expression of ADAMTS1 was low in wild-type em-
bryos until E12.5, when it became highly expressed in the endo-
cardium (marked by Tie1 expression) and persisted through
E14.5 (Figures 8A–8F). Consistent with this observation, theDeveamount of cardiac jelly diminished at E12.5, and was essentially
absent by E14.5, when the ventricular endocardium andmyocar-
dium were in continuous direct contact (Figures 8G–8I). Further-
more, the ADAMTS1 substrate, Versican, dramatically de-
creased in expression in the ventricular cardiac jelly at E12.5,
and is essentially absent by E14.5 (Figures 8J–8L). Since myo-
cardial trabeculation terminates during the period from E12.5
to E14.5, the increase in ADAMTS1 expression and subsequent
dissolution of the cardiac jelly might be required to prevent ex-
cessive trabeculation. We tested this idea by examining the
phenotype of mice lacking ADAMTS1. While ADAMTS1/ mice
exhibited approximately 50% embryonic lethality, they were
grossly normal at E13.5 (Figures 8M and 8N). At E13.5, the ven-
tricles of ADAMTS1/ embryos had increased trabecular mus-
cle (Figures 8O and 8P). We quantitated the extent of myocardial
dysmorphogenesis by morphometric measurements of the left
ventricles of 3ADAMTS1+/ and 5ADAMTS1/ E13.5 embryos.
ADAMTS1/ embryos had a statistically significant increase in
the ratio of trabecular area to total ventricle area (0.85 ± 0.07lopmental Cell 14, 298–311, February 2008 ª2008 Elsevier Inc. 305
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(A–D) Whole mount images of wild-type and Tie2Cre;Brg1F/F embryos grown in culture for 36 hr beginning at E9.0 in the presence or absence of 20 mMGM6001,
an ADAMTS1 inhibitor.
(E–H) Heart ventricle sections of the embryos shown in (A–D) are stained with Alcian blue to mark mucopolysaccharide components of the cardiac jelly and coun-
terstained using nuclear fast red.
(I–L) Anti-Versican antibody staining in the ventricular cardiac jelly of the same cultured wild-type and Tie2Cre;Brg1F/F embryos control-treated or treated with
GM6001. The sections are counterstained with hematoxylin.
(M) The mean ratio of trabecular to outside length of the left ventricle measured on H&E stained sections is graphed for wild-type and Tie2Cre;Brg1F/F embryos
culturedwith or without thematrix proteinase inhibitor GM6001 for 36 hr beginning at E9.0. Error bars represent one standard deviation. n = 3Wild-type/ND,Wild-
type/GM6001, and Tie2Cre;Brg1F/F/ND groups, n = 8 Tie2Cre;Brg1F/F/GM6001. P values were determined using Student’s t tests.
(N and O) Biotinylated-HABP stained heart sections of Tie2Cre;Brg1F/F embryos cultured from E9.0 for 36 hr in the presence or absence of GM6001 to mark
hyaluronan content (in brown). The sections are counterstained with hematoxylin (blue).to 0.58 ± 0.11, p < 0.04; Figure 8Q). There was no change in the
number of trabeculae normalized to the ventricle length (0.04 ±
0.007 to 0.04 ± 0.005, p < 0.83), trabeculae width (14.1 ± 1.2
to 13.7 ± 0.6, arbitrary units, p < 0.67), or compact layer thick-
ness (31.7 ± 2.8 to 33.0 ± 3.2, arbitrary units, p < 0.57;
Figure S9). These findings suggest that the normal upregula-
tion of ADAMTS1 at E12.5 terminates trabeculation by reconfi-
guring the extracellular matrix (Figure 8R). The transition from
repression to activation of ADAMTS1 ensures the proper micro-306 Developmental Cell 14, 298–311, February 2008 ª2008 Elsevierenvironment is present for initial support of trabecular growth
and then its termination once sufficient trabeculation has
occurred.
DISCUSSION
The trabeculation defects in Tie2Cre;Brg1F/F embryos are
caused by derepression of ADAMTS1, which encodes a matrix
metalloproteinase that degrades cardiac jelly and preventsInc.
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of hyalectans, including Versican (Kuno et al., 2000; Rodriguez-
Manzaneque et al., 2002). Although ADAMTS1-deficient mice
have not been previously examined for cardiac abnormalities,
ADAMTS1 has been implicated in cleaving Versican within the
endocardial cushion cardiac jelly to facilitate the remodeling of
the cushions into atrial and ventricular septa as well as the valve
leaflets (Kern et al., 2006). Versican contains hyaluronan-binding
domains (LeBaron et al., 1992) which may be important for es-
tablishment of an elaborate glycosaminoglycan-containing net-
work within the cardiac jelly. Therefore, inactivation of Versican
by the observed upregulation of ADAMTS1 in Tie2Cre;Brg1F/F
Figure 8. An Increase in Expression of
ADAMTS1 in Ventricular Endocardium
Terminates Myocardial Trabeculation by
Breaking Down Cardiac Jelly
(A–F) In situ hybridizations on ventricle sections of
wild-type embryos of the indicated stages for
ADAMTS1 (A–C) and Tie1 (D–F) transcripts.
Transcripts are stained brown and the slides are
counterstained with hematoxylin. Arrows indicate
ventricular endocardial cells.
(G–I) Alcian blue stained sections of wild-type
embryonic hearts of the indicated stages. The sec-
tions are counterstained with nuclear fast red.
(J–L) Sections from E10.5, E12.5, and E14.5
wild-type ventricles are stained with anti-Versican
antibodies (brown) and counterstained with hema-
toxylin.
(M and N) Gross images of E13.5 ADAMTS1+/
and littermate ADAMTS1/ embryos.
(OandP)H&Estainedsectionsof the ventriclesofan
E13.5 ADAMTS1+/ and littermate ADAMTS1/
embryos.
(Q) The mean ratio of trabecular/ventricle area in
E13.5 ADAMTS1+/ and littermate ADAMTS1/
hearts from measurements of H&E-stained left
ventricle sections (n = 3 ADAMTS1+/, n = 5
ADAMTS1/, error bars represent one standard
deviation, p < 0.04 by two-sample two-tailed Stu-
dent’s t test).
(R) A working model of myocardial trabeculation.
Brg1 represses ADAMTS1 in endocardial cells to
allow myocardial cells to produce an extracellular
environment that supports trabeculation. By
E12.5, BAF-complex mediated repression of
ADAMTS1 is relieved (by an unknownmechanism,
‘‘X’’) dissipating the cardiac jelly and preventing
excessive trabeculation. In Tie2Cre;Brg1F/F
embryos, ADAMTS1 is derepressed, causing the
cardiac jelly to prematurely break down and dis-
rupting myocardial morphogenesis.
embryos could facilitate the degradation
of hyaluronan, which then directly leads
to collapse of ventricular cardiac jelly.
This notion is supported by studies show-
ing that addition of hyaluronidase to
whole rat embryo cultures causes col-
lapse of ventricular cardiac jelly and leads
to trabeculation defects (Baldwin and
Solursh, 1989).
There are several ways how cardiac jelly composition could
influence myocardial trabeculation. During trabeculation, both
myocardial and endocardial cells must undergo extensive cellu-
lar movements to form the long thin projections protruding into
the ventricular cavity. Therefore, establishment of an appropriate
extracellular milieu that facilitates changes in cell shape, adhe-
sion, or migration may be critical for trabeculation. Second,
ECM components could regulate trabeculation by providing a
permissive environment for diffusion or posttranslational modifi-
cation of signaling molecules involved in trabeculation, including
Notch (Grego-Bessa et al., 2007), Neuregulin (Meyer and Birch-
meier, 1995;Meyer et al., 1997), EphrinB2 (Gerety and Anderson,Developmental Cell 14, 298–311, February 2008 ª2008 Elsevier Inc. 307
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1993, 1995; Suri et al., 1996). In particular, VEGFR2 signaling
in embryonic stem cells is promoted by heparan sulfate proteo-
glycans produced by adjacent cells (Jakobsson et al., 2006) and
heparan sulfate modulates VEGF gradients (Ruhrberg et al.,
2002). Third, certain components of the ECM are active signaling
molecules themselves or can directly modify the ability of signal-
ingmolecules to act on their receptors. For example, HA binds to
the CD44 and LYVE-1 cell receptors, and activates intracellular
signaling (Aruffo et al., 1990; Banerji et al., 1999). HA is also a
cofactor for neuregulin signaling (Bourguignon et al., 1997; Ca-
menisch et al., 2002). Therefore, regulated changes in the micro-
environment of the heart ventricle during development could
facilitate a developmental transition to terminate cardiac trabe-
culation independent of the expression of the signaling factors
involved.
A specific human congenital cardiomyopathy, termed spongy
myocardium, hypertrabeculation, or noncompaction of the myo-
cardium, reflects developmental defects during the trabecula-
tion process. The genetic lesions underlying this disease remain
obscure. Hearts of these patients exhibit excessive trabeculation
and develop congestive heart failure with the only treatment be-
ing a heart transplant. Our observation that premature expres-
sion of ADAMTS1 in the absence of endocardial Brg1 prevents
trabeculation suggests that the normal increase in endocardial
ADAMTS1 expression during development is essential to pre-
vent hypertrabeculation. Interestingly, overexpression of a non-
cleavable form of Versican in embryonic chick hearts causes
a thickening of the right ventricle and possibly hypertrabecula-
tion (Kern et al., 2007). Here, we show that ADAMTS1/ mice,
a genotype which is approximately 50% embryonically lethal
(Mittaz et al., 2004; Shindo et al., 2000), develop excessive trabe-
culation. This result supports a model in which Brg1 represses
expression of ADAMTS1 until developmental cues alleviate the
repression around E12.5 to facilitate the termination of trabecu-
lation (Figure 8R). The increase in ADAMTS1 prevents excessive
trabeculation by breaking down ventricular cardiac jelly and
altering the microenvironment that supports cellular movements
and/or signaling events. Subsequently, the heart develops the
thick compact layer that provides the extensive muscular power
required in a mature heart. ADAMTS1/ embryos that escape
embryonic lethality and survive to adulthood do not have appar-
ent noncompaction of the ventricles (data not shown). Therefore,
additional cardiac jelly degrading enzymes may cooperate with
ADAMTS1 in a partially redundant fashion to terminate trabecu-
lation. Candidates include additional ADAMTS proteins or mem-
bers of the MMP family, some of which are expressed in the de-
veloping heart (Figures S5 and S6; Ratajska and Cleutjens, 2002)
and whose substrates also include proteoglycans (reviewed in
Flannery, 2006). A detailed understanding of the roles of cardiac
jelly regulators during heart development may help identify can-
didate genes mutated in families with congenital cardiomyopa-
thy and eventually lead to novel treatments for these diseases.
Activities of chromatin remodeling enzymes are commonly as-
sociated with transcriptional activation given their ability to
loosen chromatin to facilitate the access of transcription factors
and transcriptional machinery. Therefore, although a number of
genes have been described as being repressed by the BAF com-
plex (reviewed in de la Serna et al., 2006), it is surprising to find308 Developmental Cell 14, 298–311, February 2008 ª2008 Elsevierthat a critical function of theBAF complex in developing endocar-
dial cells is as a site-specific transcriptional repressor.WhileBrg1
directly associates with the ADAMTS1 locus, it remains to be de-
termined how the BAF complex is recruited and how it mediates
repression. Since Brg1 remains ubiquitously expressed through-
out heart development (FigureS10), changes inBrg1 levelsdonot
account for the normal derepression ofADAMTS1. Therefore, re-
cruitment factors likely provide active regulation of the locus. Al-
ternatively, a change in activity of the BAF complex onADAMTS1
may lie in a developmental switch in the combinatorial assembly
of homologousBAFsubunits,which canproduce differential BAF
complex activities in specific cell types (Lessard et al., 2007).
Our findings demonstrate an unexpectedly specific role for
the BAF complex in maintaining transcriptional repression of
ADAMTS1 in developing endocardial cells to establish the appro-
priate microenvironment for trabeculation of the ventricles. The
connection between theBAFcomplex and regulation of themicro-
environment in the developing heart ventricle raises an intriguing
possibility that chromatin-based regulation may be a common
source for the establishment of extracellular environments. Recent
reports indicate an analogous relationship to that between Brg1
and ADAMTS1 exists between the histone deacetylase HDAC7
andMMP10 in the developing vasculature (Chang et al., 2006) and
between HDACs and ECM components during worm develop-
ment (Whetstine et al., 2005). Furthermore, Brg1 has been impli-
cated in regulating the expression ofMMP2 andMMP9 in cultured
cells (Ma et al., 2004a, 2004b). Chromatin regulation may provide
a source for signaling specificity bymodifying the ability of intercel-
lular signals to be transmitted in a complex environment. This
premise may have broad implications given the important roles
of chromatin remodeling and themicroenvironment in both normal
and pathologic settings (Anderson et al., 2006; Bhowmick et al.,
2004;RobertsandOrkin, 2004) of tissuegrowthanddifferentiation.
EXPERIMENTAL PROCEDURES
Mouse Husbandry
All mouse strains were maintained in outbred backgrounds. The targeted null
allele of Brg1, Brg1 (Bultman et al., 2000), the loxP allele of Brg1, Brg1F (Indra
et al., 2005), Tie2Cre (Kisanuki et al., 2001), Sm22aCre (Holtwick et al., 2002),
Rosa26RLacZ (Soriano, 1999), and ADAMTS1 (Lee et al., 2006) strains are de-
scribed. For tissue specific deletions, males of genotype Tie2Cre;Brg1F/+were
crossedwithBrg1F/F females. The date of observation of a vaginal plugwas set
as embryonic day E0.5, which was confirmed by ultrasonography prior to sac-
rificing pregnant mice (Chang et al., 2003) and examination of embryo mor-
phology and somite number. Identical styles of crosses were usedwith Sm22a
Cre deletion of Brg1.
Immunostaining
For the antibody staining of paraffin sections we used standard methods, fol-
lowing protocols detailed in the Supplemental Experimental Procedures. The
following antibodies were used: anti-Brg1 (G7) mouse monoclonal (Santa
Cruz Biotechnology), anti-Brg1 rabbit polyclonal (Chemicon), anti-Brg1 (J1)
rabbit polyclonal, anti-NFATc1 (7A6) (BD Biosciences), anti-smooth muscle
actin (Sigma), anti-Actinin (Sigma), anti-phospho-Histone H3 (Millipore), anti-
Versican (Millipore), anti-Perlecan (SPM255) (Santa Cruz Biotechnology),
and anti-Neo-Versican (anti-Versican V0/V1Neo) (Affinity Bioreagents). TUNEL
staining was performed using an in situ cell death detection kit (Roche).
Histology
Paraffin sections were prepared as described in the immunostaining section.
Following rehydration, the slides were consecutively stained with hematoxylinInc.
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to imaging. Alcian blue staining was performed using a 1% solution of Alcian
blue (pH 2.5) in acetic acid followed by counterstaining with Nuclear Fast
Red (Vector Laboratories). Hyaluronan was stained using biotinylated-hyalur-
onan binding protein (Calbiochem) at 4 mg/ml, HRP-conjugated streptavidin
(DAKO), and DAB chromogenic development. The sections were counter-
stained with hematoxylin.
Trabeculation Quantification
We used a dual-fluorescence confocal image system similar to one previously
described (Chen et al., 2004) to visualize, quantitate, and compare the devel-
opment of trabecular myocardium in Tie2Cre;Brg1F/F and littermate control
embryos. Frozen sections of the embryos were stained with anti-PECAM
(BD Biosciences) and anti-MF20 (Developmental Studies Hybridoma Bank)
antibodies (described further in the Supplemental Data). The imageswere cap-
tured using LaserSharp software and analyzed with Metamorph (version 6.1).
We measured the thickness of trabecular ridges/sheets (mm), thickness of
compact wall (mm), and area of trabecular myocardium normalized by the
length of compact wall (mm2/mm). For the ADAMTS1 null and heterozygous
control mice, a modification of the above protocol was used for morphometric
measurements of the hearts. We performed the quantification using images of
H&E stained paraffin sections analyzed with Nikon Advanced Elements soft-
ware. We measured the total number of trabeculae (where the trabecular layer
meets the compact layer) normalized to ventricle length, the average thickness
of the trabeculae, the average thickness of the compact layer, and the total
area of the trabecular sheet normalized to the area of the ventricle (in pixel
units). These latter ratios do not represent absolute ratios as the normalization
measurements were performed using images taken at a different magnifica-
tion.
Whole Mount In Situ Hybridization
In situ hybridization assays were based on the protocol described in Wilkinson
andNieto (1993), with details andmodifications described in the Supplemental
Experimental Procedures. The plasmid template for theBMP10 in situ probe is
described (Chen et al., 2004).
In Situ Hybridization on Paraffin Sections
Digoxigenin-labeled antisense transcripts were synthesized using plasmid
templates (Roche). Plasmids for synthesizing the probes are from the following
sources: VEGF-A from Douglas Hanahan (Christofori et al., 1995), neuregulin
from Carmen Birchmeier (Meyer et al., 1997), Tie2 from Kari Alitalo (Korhonen
et al., 1994), Has-2 from Todd Camenisch (Camenisch et al., 2000), Tie1,
VEGFR2, Nkx2.5, GATA4, ErbB2, Hey1, MEF2C, NPPA, UGDH, versican,
perlecan, Irx4, MEST, TIMP3, Hyal1, Hyal2, Hyal3, ADAMTS1, ADAMTS4,
ADAMTS5, ADAMTS8, ADAMTS9, ADAMTS18, MMP1, MMP2, MMP3,
MMP9, MMP13, and fibulin1 from Open Biosystems. All plasmids were
confirmed by sequencing. Details for probe hybridization and visualization
are included in the Supplemental Experimental Procedures.
RT-PCR and Quantitative RT-PCR
Whole hearts were dissected from E9.5 embryos. The hearts were disrupted in
Trizol (Invitrogen) and RNAwas purified using standardmethods. One hundred
and fifty nanograms of total RNA from each sample was used as a template to
prepare cDNA using the Superscript III reverse transcription system (Invitro-
gen). In the case of HUVECs, RNA was isolated using a Trizol-based method
and 500 ng of RNAwas used for cDNA synthesis. Quantitative PCR tomeasure
transcript content in the individual samples was performed using primers and
is described in the Supplemental Experimental Procedures.
Lentivirus Production and RNA Interference
Lentivirus were produced in 293T cells following protocols of the Didier Trono
lab by cotransfecting them with packaging and envelope plasmids and pGIPZ
transfer vectors for shRNA expression (Open Biosystems). Two separate plas-
mids expressing shRNAs targeting human Brg1 were used while the control
pGIPZ vector contains a nonsilencing shRNA. Two days posttransfection of
the 293T cells, the media was isolated, filtered, and concentrated using
a 100k MW cutoff centrifugal filter unit (Millipore). This viral concentrate was
used for transduction of HUVECs. The cells were cultured for 5 d, at whichDevepoint most of the cells expressed GFP, indicating a high rate of infection.
RNA was prepared using Trizol extractions and then used for cDNA synthesis.
Expression levels were determined using quantitative RT-PCR as described
above.
Chromatin Immunoprecipitations
HUVECs were cultured to approximately 75% confluency on six 15 cm plates
and harvested using reagents and methods from a chromatin immunoprecip-
itation kit (Upstate) withmodifications and details described in the Supplemen-
tal Experimental Procedures. Chromatin was prepared and immunoprecipi-
tated using the J1 anti-Brg1 antibody (Wang et al., 1996) and an anti-GFP
(Invitrogen) antibody as an isotype-matched negative control. Following
washes, DNA was retrieved and used for quantitative PCR using primers
and methods described in the Supplemental Experimental Procedures.
Reporter Assays
Reporter plasmids were constructed by cloning PCR amplified regions of the
mouse ADAMTS1 locus into the episomal pREP4-Luc plasmid (Liu et al.,
2001). These vectors, along with an episomal Renilla-luciferase plasmid
(pREP7-RL) to normalize for transfection efficiency and a plasmid expressing
human Brg1 or a matching empty vector plasmid, were transfected into SW13
cells using lipofectamine 2000 (Invitrogen). The cells were cultured for 2 d and
harvested for luciferase assay using the dual luciferase assay kit (Promega).
Whole Embryo Culture
Whole embryo cultures were performed as described (Chang et al., 2004). Em-
bryos were isolated intact in their yolk sacs at E9.0 and cultured for 36 hr in the
presence of either 20 mM GM6001 (Calbiochem), 20 mM Minocycline (Sigma),
or an equivalent amount of DMSO alone. The yolk sacs were used for genotyp-
ing and the embryos harvested for histological analysis.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures and
ten figures and are available with this article online at http://www.
developmentalcell.com/cgi/content/full/14/2/298/DC1/.
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